Cargando…

New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy

Photodynamic therapy (PDT) is a cancer treatment modality that requires three components, namely light, dioxygen and a photosensitizing agent. After light excitation, the photosensitizer (PS) in its excited state transfers its energy to oxygen, which leads to photooxidation reactions. In order to im...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamarulzaman, Ezatul Ezleen, Mohd Gazzali, Amirah, Acherar, Samir, Frochot, Céline, Barberi-Heyob, Muriel, Boura, Cédric, Chaimbault, Patrick, Sibille, Estelle, Wahab, Habibah A., Vanderesse, Régis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632738/
https://www.ncbi.nlm.nih.gov/pubmed/26473840
http://dx.doi.org/10.3390/ijms161024059
_version_ 1782399084901957632
author Kamarulzaman, Ezatul Ezleen
Mohd Gazzali, Amirah
Acherar, Samir
Frochot, Céline
Barberi-Heyob, Muriel
Boura, Cédric
Chaimbault, Patrick
Sibille, Estelle
Wahab, Habibah A.
Vanderesse, Régis
author_facet Kamarulzaman, Ezatul Ezleen
Mohd Gazzali, Amirah
Acherar, Samir
Frochot, Céline
Barberi-Heyob, Muriel
Boura, Cédric
Chaimbault, Patrick
Sibille, Estelle
Wahab, Habibah A.
Vanderesse, Régis
author_sort Kamarulzaman, Ezatul Ezleen
collection PubMed
description Photodynamic therapy (PDT) is a cancer treatment modality that requires three components, namely light, dioxygen and a photosensitizing agent. After light excitation, the photosensitizer (PS) in its excited state transfers its energy to oxygen, which leads to photooxidation reactions. In order to improve the selectivity of the treatment, research has focused on the design of PS covalently attached to a tumor-targeting moiety. In this paper, we describe the synthesis and the physico-chemical and photophysical properties of six new peptide-conjugated photosensitizers designed for targeting the neuropilin-1 (NRP-1) receptor. We chose a TPC (5-(4-carboxyphenyl)-10,15, 20-triphenyl chlorine as photosensitizer, coupled via three different spacers (aminohexanoic acid, 1-amino-3,6-dioxaoctanoic acid, and 1-amino-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid) to two different peptides (DKPPR and TKPRR). The affinity towards the NRP-1 receptor of the conjugated chlorins was evaluated along with in vitro and in vivo stability levels. The tissue concentration of the TPC-conjugates in animal model shows good distribution, especially for the DKPPR conjugates. The novel peptide–PS conjugates proposed in this study were proven to have potential to be further developed as future NRP-1 targeting photodynamic therapy agent.
format Online
Article
Text
id pubmed-4632738
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-46327382015-11-23 New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy Kamarulzaman, Ezatul Ezleen Mohd Gazzali, Amirah Acherar, Samir Frochot, Céline Barberi-Heyob, Muriel Boura, Cédric Chaimbault, Patrick Sibille, Estelle Wahab, Habibah A. Vanderesse, Régis Int J Mol Sci Article Photodynamic therapy (PDT) is a cancer treatment modality that requires three components, namely light, dioxygen and a photosensitizing agent. After light excitation, the photosensitizer (PS) in its excited state transfers its energy to oxygen, which leads to photooxidation reactions. In order to improve the selectivity of the treatment, research has focused on the design of PS covalently attached to a tumor-targeting moiety. In this paper, we describe the synthesis and the physico-chemical and photophysical properties of six new peptide-conjugated photosensitizers designed for targeting the neuropilin-1 (NRP-1) receptor. We chose a TPC (5-(4-carboxyphenyl)-10,15, 20-triphenyl chlorine as photosensitizer, coupled via three different spacers (aminohexanoic acid, 1-amino-3,6-dioxaoctanoic acid, and 1-amino-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid) to two different peptides (DKPPR and TKPRR). The affinity towards the NRP-1 receptor of the conjugated chlorins was evaluated along with in vitro and in vivo stability levels. The tissue concentration of the TPC-conjugates in animal model shows good distribution, especially for the DKPPR conjugates. The novel peptide–PS conjugates proposed in this study were proven to have potential to be further developed as future NRP-1 targeting photodynamic therapy agent. MDPI 2015-10-12 /pmc/articles/PMC4632738/ /pubmed/26473840 http://dx.doi.org/10.3390/ijms161024059 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kamarulzaman, Ezatul Ezleen
Mohd Gazzali, Amirah
Acherar, Samir
Frochot, Céline
Barberi-Heyob, Muriel
Boura, Cédric
Chaimbault, Patrick
Sibille, Estelle
Wahab, Habibah A.
Vanderesse, Régis
New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy
title New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy
title_full New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy
title_fullStr New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy
title_full_unstemmed New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy
title_short New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy
title_sort new peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1 for anti-vascular targeted photodynamic therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632738/
https://www.ncbi.nlm.nih.gov/pubmed/26473840
http://dx.doi.org/10.3390/ijms161024059
work_keys_str_mv AT kamarulzamanezatulezleen newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT mohdgazzaliamirah newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT acherarsamir newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT frochotceline newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT barberiheyobmuriel newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT bouracedric newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT chaimbaultpatrick newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT sibilleestelle newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT wahabhabibaha newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy
AT vanderesseregis newpeptideconjugatedchlorintypephotosensitizertargetingneuropilin1forantivasculartargetedphotodynamictherapy